NDAORALPELLETSPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
MAVYRET (glecaprevir and pibrentasvir) by AbbVie is p-glycoprotein inhibitors [moa]. First approved in 2021.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAVYRET is an oral fixed-dose combination of glecaprevir and pibrentasvir for the treatment of chronic hepatitis C virus (HCV) infection. It functions as a P-glycoprotein inhibitor and NS5A inhibitor, targeting viral replication mechanisms. This pangenotypic therapy offers simplified, shortened treatment regimens across HCV genotypes.
Peak9.5 years to LOE
Product is at peak commercial penetration with established market presence; commercial teams are likely optimized and focused on maintaining market share rather than expansion.
Mechanism of Action
P-Glycoprotein Inhibitors
Pharmacologic Class:
Hepatitis C Virus NS5A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Started Feb 2017
10 enrolled
Chronic Kidney DiseaseChronic Hepatitis C
Career Relevance
MAVYRET roles are concentrated in commercial and medical affairs functions that support a mature, established franchise. Working on this product provides stability and specialization in hepatology, though innovation opportunities are limited given the peak lifecycle stage and declining HCV incidence.
Brand Manager
Worked on MAVYRET at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.